Phio Pharma Takes RXi’s Self-Delivering RNAi Technology, Refocuses On Immuno-Oncology

 
• By Joseph Haas
  
railroad-tracks
Phio's name change reflects its new therapeutic focus on IO

More from Strategy

More from Business